<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="179611">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756691</url>
  </required_header>
  <id_info>
    <org_study_id>SP-24367</org_study_id>
    <nct_id>NCT00756691</nct_id>
  </id_info>
  <brief_title>A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA</brief_title>
  <official_title>A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoxia (little of no oxygen) is considered to be an important characteristic of a patient's
      tumour that may help predict patient outcomes and/or help inform patient management
      decisions. 18F-FAZA Positron Emission Tomography (PET) can detect hypoxic tumours because
      18F-FAZA accumulates in hypoxic tissues. This study is being done to learn more about the
      processes by which 18F-FAZA is absorbed, distributed, metabolized (built-up and broken down)
      and eliminated by the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I Radiopharmacokinetic and Radiodosimetric study of 18F-FAZA. Prior to treatment,
      subjects will receive a single injection of 18F-FAZA. Subjects will undergo a series of 5-5
      PET scans, and will have 8-13 blood samples and 2 urine samples taken at specified time
      points over a 4.5-5.5 hour period. 18F-FAZA PET images will be reviewed to develop a dynamic
      uptake model, and blood and urine samples will be analyzed for unchanged 18F-FAZA and its
      metabolites.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To Collect imaging-based data for radiopharmacokinetic and radiodosimetric analyses.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine radiation dosimetry and optimal imaging times</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypoxic Tumours</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>First 5 consecutive 18F-FAZA avid subjects that undergo up to 5 PET scans, 13 blood and 2 urine samples over 4.5 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Next 5 consecutive 18F-FAZA avid subjects that undergo up to 4 PET scans, 8 blood and 2 urine samples over 5.5 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-FAZA</intervention_name>
    <description>Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known primary or suspected metastatic carcinoma of the following: squamous
        cell carcinoma (SCC) of the head and neck, small (SCLC) and non-small cell lung
        cancer(NSCLC), Glioblastoma multiforme (GBM), lymphoma, or neuroendocrine tumours (NET).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male of Female &gt; or = to 18 years of age. If female of child-bearing potential and
             outside of the window of 10 days since the first day of the last menstrual period, a
             negative pregnancy test required

          -  Subjects with known primary or suspected metastatic SCC head and neck; NSCLC; SCLC;
             GBM; lymphoma, or NET with at least one lesion &gt; 1 cm in diameter

          -  Able and willing to follow instructions and comply with the protocol

          -  Provide written informed consent prior to participation in the study

          -  Karnofsky Performance Scale Score of 70-100

        Exclusion Criteria:

          -  Previous treatment for their primary or metastatic SCC head and neck, NSCLC, SCLC,
             GBM, Lymphoma, or NET

          -  Bilirubin &gt; or = to 200 umol/L

          -  Creatinine &gt; or - to 150 umol/L

          -  AST or ALT &gt; or = to 5 times the upper limits of normal

          -  Serious medical conditions such as: congestive heart failure, unstable angina,
             unstable ventricular arrhythmia, uncontrolled psychiatric conditions, serious
             infections, uncontrolled diabetes

          -  Nursing or pregnant females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander J. B. McEwan, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHS Cancer Control Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lai Schrader</last_name>
    <phone>780-432-8464</phone>
    <email>Lai.Schrader@albertahealthservices.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>708-432-8464</phone>
    </contact>
    <investigator>
      <last_name>Alexander J. B. McEwan, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve McQuarrie, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonard I. Wiebe, DSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>18F-FAZA</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Radiation dosimetry</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
